Ocugen, Inc. (OCGN)

1,3200 -0,0700 (-5,04%) Al cierre: 04:00PM EDT

Ocugen, Inc.

11 Great Valley Parkway
Malvern, PA 19355
United States
484 328 4701
https://www.ocugen.com

Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 65

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Dr. Shankar Musunuri M.B.A., Ph.D.	Co-Founder, CEO & Chairman	1,2M	1,26M	1964
Dr. Uday B. Kompella Ph.D.	Co-founder & Independent Director	56,72k	N/A	1967
Mr. Michael Breininger CPA, M.B.A.	Interim Chief Accounting Officer & Principal Financial Officer and Corporate Controller	N/A	N/A	1982
Dr. Arun Upadhyay Ph.D.	Chief Scientific Officer and Head of Research & Development	N/A	N/A	1983
John Kouch J.D.	General Counsel	N/A	N/A	N/A
Ms. Tiffany J. Hamilton M.B.A.	Head of Corporate Communications	N/A	N/A	N/A
Dr. Durgaprasad Annavajjula Ph.D.	VP, Head of Program Management & Chief of Staff	N/A	N/A	N/A
Mr. Michael Shine M.B.A.	Senior Vice President of Commercial	N/A	N/A	N/A
Ms. Jyothy Pillai M.S.	Head of Regulatory & Quality	N/A	N/A	N/A
Dr. Huma Qamar CMI, M.D., M.P.H.	Chief Medical Officer	N/A	N/A	N/A

Los importes son a partir de 31 de diciembre de 2022 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.

Gobierno corporativo

El ISS Governance QualityScore de Ocugen, Inc., a día 29 de abril de 2024, es 9. Las puntuaciones base son Auditoría: 4; Tablero: 7; Derechos de los accionistas: 8; Compensación: 10.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.